Exelixis
EXEL
#1725
Rank
NZ$16.81 B
Marketcap
$58.86
Share price
-1.16%
Change (1 day)
57.81%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total debt

Total debt on the balance sheet as of September 2024 : NZ$0.34 Billion

According to Exelixis's latest financial reports the company's total debt is NZ$0.34 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Exelixis - Total debt on balance sheet (from 2000 to 2024)

Total debt by year

Year Total debt Change
2023-12-31NZ$0.30 B0.28%
2022-12-31NZ$0.29 B299.03%
2021-12-31NZ$75.06 M10.34%
2020-12-31NZ$68.02 M-4.57%
2019-12-31NZ$71.28 M220.58%
2018-12-31NZ$22.23 M5.72%
2017-12-31NZ$21.03 M-92.3%
2016-12-31NZ$0.27 B-55.29%
2015-12-31NZ$0.61 B34.03%
2014-12-31NZ$0.45 B7.82%
2013-12-31NZ$0.42 B3.54%
2012-12-31NZ$0.40 B75.48%
2011-12-31NZ$0.23 B-13.93%
2010-12-31NZ$0.27 B146.5%
2009-12-31NZ$0.10 B-45.94%
2008-12-31NZ$0.20 B27.83%
2007-12-31NZ$0.15 B-8.13%
2006-12-31NZ$0.17 B-20.71%
2005-12-31NZ$0.21 B5.46%
2004-12-31NZ$0.20 B20.85%
2003-12-31NZ$0.17 B20.96%
2002-12-31NZ$0.14 B19.86%
2001-12-31NZ$0.11 B249.37%
2000-12-31NZ$33.73 M32.56%
1999-12-31NZ$25.44 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
NZ$38.00 B 10,953.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
NZ$45.01 B 12,994.04%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$67.42 B 19,510.17%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$90.88 B 26,334.21%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$106.79 B 30,961.74%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$63.21 B 18,286.18%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$117.79 B 34,160.07%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$5.76 M-98.32%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$68.39 M-80.11%๐Ÿ‡บ๐Ÿ‡ธ USA